Nuclear medicine vendor ADAC Laboratories continues to be plagued by accounting snafus. The Milpitas, CA, company announced May 19 that it will delay the release of its financial results for the second quarter (end-April) as it evaluates whether
Nuclear medicine vendor ADAC Laboratories continues to be plagued by accounting snafus. The Milpitas, CA, company announced May 19 that it will delay the release of its financial results for the second quarter (end-April) as it evaluates whether to establish additional reserves and one-time charges. The additional reserves are for lower results in Europe and Latin America, while the company did not indicate the reason for the additional charges.
ADAC has been struggling with accounting problems since late 1998, when it announced that it would have to restate revenues for the past three years (SCAN 12/16/98). The news prompted the filing of a half-dozen shareholder lawsuits and caused investors to dump ADAC shares. Last weeks news only exacerbated the situation: ADAC shares were trading at about $8.25 on May 20, down almost 14%.
© 1999 Miller Freeman, Inc.All rights reserved.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.